JP2021515017A5 - - Google Patents

Info

Publication number
JP2021515017A5
JP2021515017A5 JP2020546443A JP2020546443A JP2021515017A5 JP 2021515017 A5 JP2021515017 A5 JP 2021515017A5 JP 2020546443 A JP2020546443 A JP 2020546443A JP 2020546443 A JP2020546443 A JP 2020546443A JP 2021515017 A5 JP2021515017 A5 JP 2021515017A5
Authority
JP
Japan
Prior art keywords
cancer
optionally
subject
antibody
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020546443A
Other languages
English (en)
Japanese (ja)
Other versions
JP7471227B2 (ja
JP2021515017A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/021024 external-priority patent/WO2019173523A1/en
Publication of JP2021515017A publication Critical patent/JP2021515017A/ja
Publication of JP2021515017A5 publication Critical patent/JP2021515017A5/ja
Priority to JP2024002970A priority Critical patent/JP2024045219A/ja
Application granted granted Critical
Publication of JP7471227B2 publication Critical patent/JP7471227B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020546443A 2018-03-07 2019-03-06 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用 Active JP7471227B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024002970A JP2024045219A (ja) 2018-03-07 2024-01-12 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862639891P 2018-03-07 2018-03-07
US62/639,891 2018-03-07
US201862736343P 2018-09-25 2018-09-25
US62/736,343 2018-09-25
PCT/US2019/021024 WO2019173523A1 (en) 2018-03-07 2019-03-06 Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024002970A Division JP2024045219A (ja) 2018-03-07 2024-01-12 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用

Publications (3)

Publication Number Publication Date
JP2021515017A JP2021515017A (ja) 2021-06-17
JP2021515017A5 true JP2021515017A5 (https=) 2022-03-14
JP7471227B2 JP7471227B2 (ja) 2024-04-19

Family

ID=67845742

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020546443A Active JP7471227B2 (ja) 2018-03-07 2019-03-06 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用
JP2024002970A Pending JP2024045219A (ja) 2018-03-07 2024-01-12 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024002970A Pending JP2024045219A (ja) 2018-03-07 2024-01-12 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用

Country Status (13)

Country Link
US (1) US20210030888A1 (https=)
EP (1) EP3762032A4 (https=)
JP (2) JP7471227B2 (https=)
KR (1) KR20200130356A (https=)
CN (1) CN112105388A (https=)
AU (1) AU2019231696B2 (https=)
BR (1) BR112020018092A2 (https=)
CA (1) CA3091217A1 (https=)
IL (1) IL276768A (https=)
MX (1) MX2020008613A (https=)
SG (1) SG11202007865VA (https=)
UA (1) UA129351C2 (https=)
WO (1) WO2019173523A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
TW202506732A (zh) 2018-05-07 2025-02-16 丹麥商珍美寶股份有限公司 使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
WO2022111618A1 (zh) * 2020-11-26 2022-06-02 正大天晴药业集团股份有限公司 用于治疗肺癌的抗PD-L1抗体和c-Met激酶抑制剂的联用药物组合物
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
CN114569734B (zh) * 2022-01-17 2023-08-29 北京化工大学 一种基于还原敏感聚合物递送阳离子铂药的纳米粒的制备方法
WO2023213960A1 (en) * 2022-05-06 2023-11-09 Genmab A/S Methods of treating cancer with anti-tissue factor antibody-drug conjugates
WO2024067864A1 (en) * 2022-09-30 2024-04-04 Shanghai Junshi Biosciences Co., Ltd. Anti-lair1 antibodies and their uses
KR20250057675A (ko) * 2023-10-19 2025-04-29 (주)셀트리온 캄프토테신 유도체를 포함하는 항-Tissue factor 항체-약물 접합체

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA109633C2 (uk) * 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
BR112012031727B1 (pt) * 2010-06-15 2022-03-29 Genmab A/S Conjugado de droga-anticorpo, composição farmacêutica, e, uso do conjugado de droga- anticorpo
PT3347054T (pt) * 2015-09-11 2021-07-15 Genmab As Regimes de dosagem para conjugados fármaco-anticorpo anti-tf

Similar Documents

Publication Publication Date Title
JP2021515017A5 (https=)
JP2021501776A5 (https=)
JP2021518394A5 (https=)
JP2021523233A5 (https=)
JP2021523158A5 (https=)
JP2021534165A5 (https=)
TW201922793A (zh) Ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合治療小細胞肺癌的用途
JP2022513386A5 (https=)
IL312038A (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
JP2023500888A5 (https=)
JP2022541591A5 (https=)
JP2023500697A5 (https=)
IL278400B2 (en) Combination of an anti pd-1 antibody and anti tissue factor (tf) antibody drug conjugate for use in the treatment of cancer
JP2022544227A5 (https=)
TW202330040A (zh) 抗ｈｅｒ２抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途
JP2025501978A5 (https=)
WO2023134706A1 (zh) 抗trop-2抗体偶联药物和其他治疗剂的组合用途
TWI870592B (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
WO2020233602A1 (zh) 用于联合治疗小细胞肺癌的喹啉衍生物
CN120437288A (zh) 治疗卵巢癌的药物组合
JP2024519907A (ja) 尿路上皮癌の治療における、免疫チェックポイント阻害剤と併用での抗体薬物複合体の使用
CN112043832A (zh) 用于联合治疗胃癌的喹啉类化合物
WO2024183643A1 (zh) 含抗tim-3抗体的药物组合
WO2023174408A1 (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
WO2024051670A1 (zh) 结合tim-3的抗体与结合pd-1的抗体的药物组合